Sernova Corp. (TSE:SVA) Expected to Earn FY2025 Earnings of ($0.10) Per Share

Sernova Corp. (TSE:SVA) – Investment analysts at Ventum Cap Mkts issued their FY2025 earnings per share (EPS) estimates for Sernova in a note issued to investors on Tuesday, September 17th. Ventum Cap Mkts analyst S. Quenneville expects that the company will post earnings of ($0.10) per share for the year. Ventum Cap Mkts has a “Strong-Buy” rating on the stock. The consensus estimate for Sernova’s current full-year earnings is ($0.08) per share.

Sernova (TSE:SVA) last posted its quarterly earnings results on Monday, September 16th. The company reported C($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of C($0.03) by C$0.01.

A number of other brokerages have also weighed in on SVA. Ventum Financial decreased their price objective on shares of Sernova from C$3.00 to C$2.50 and set a “buy” rating for the company in a report on Friday, September 13th. Leede Financial reduced their target price on Sernova from C$3.00 to C$1.50 and set a “speculative buy” rating for the company in a report on Friday, September 13th.

Sernova Stock Down 2.0 %

Shares of Sernova stock opened at C$0.25 on Thursday. The company has a 50-day simple moving average of C$0.26 and a two-hundred day simple moving average of C$0.36. Sernova has a 52-week low of C$0.20 and a 52-week high of C$0.83. The company has a debt-to-equity ratio of 16.55, a quick ratio of 18.11 and a current ratio of 0.62. The stock has a market capitalization of C$79.48 million, a PE ratio of -1.88 and a beta of 1.38.

Insider Activity

In related news, Director Steven Sangha sold 930,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of C$0.24, for a total transaction of C$223,200.00. Insiders have purchased a total of 379,600 shares of company stock valued at $97,671 in the last 90 days. 12.98% of the stock is currently owned by insiders.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.